Compounds · Tirzepatide · continued

[2026 update] Does dual agonism explain the effect size, or is it dose? posts 61–64

Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme effect size Solved

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

b.okonkwoTL21 Nov 2025#61

A note on scope: what I am saying about dual agonism applies to the case in the first post and I would not extend it further without checking.

29 likes 9mo

f.amankwahTL22 Nov 2025#62

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.

I would hold that lightly until someone with a larger sample weighs in.

0 likes 9mo

hana.satoTL43 Nov 2025#63

Collapsed as off-topic by two members at trust level 3 or above

This follows post #60 rather than contradicting it.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.

c.ostergaardTL24 Nov 2025#64

s.dziedzic, post #33: The 2.5 mg starting dose is not a therapeutic dose in the sense that weight loss is minimal at that dose. It is a tolerance-testing dose. Confusing the purpose of a starting dose with the purpose of a maintenance dose leads to false conclusions about efficacy. Go to post

Worth separating two things that post #62 runs together.

The published pharmacokinetics show dose proportionality across the studied range, which means dose arithmetic behaves the way you would naively expect. That is not true of every compound and it is worth knowing which ones it is true of.

9 likes in reply to #33 9mo

This topic was referenced in

About the Tirzepatide categoryCompounds › Tirzepatide · 6 replies
Comparing tirzepatide and semaglutide is harder than the tables suggestCompounds › Tirzepatide · 2 replies
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long versionCompounds › Tirzepatide · 90 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
About the Tirzepatide category Compounds › Tirzepatide tirzepatide SURMOUNT programme SURPASS programme Pinned Wiki Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+2	6	132	13mo
Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? Compounds › Tirzepatide SURMOUNT programme SURPASS programme effect size tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide molecular mass and the charge states you would expect on ESI — does this still hold? The question about Tirzepatide molecular mass that…	+7	11	281	6mo
Does dual agonism explain the effect size, or is it dose? Compounds › Tirzepatide SURPASS programme SURMOUNT programme tirzepatide randomised trial Solved Does dual agonism explain the effect size, or is it dose? I have a specific reason for asking rather than idle curiosity, and the context is below. A question about dual agonism that I think has a definite…	+62	68	2.6k	29d
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Compounds › Tirzepatide SURMOUNT programme randomised trial effect size tirzepatide Closed On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. A narrow question about Tirzepatide in type 2…	+85	90	13k	7mo
The 2.5 mg starting dose is not a therapeutic dose — why that matters Compounds › Tirzepatide SURPASS programme SURMOUNT programme effect size Solved The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about 2.5 mg starting dose that I…	+119	136	5.6k	2mo

Related topics — sharing the tags SURMOUNT programme, randomised trial, SURPASS programme

Topic	Participants	Replies	Views	Activity
Tirzepatide and nausea: is the profile genuinely different or just differently reported? Compounds › Tirzepatide SURMOUNT programme randomised trial SURPASS programme tirzepatide Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Asking about tirzepatide and nausea directly, because I…	+18	22	37k	8mo
Why retatrutide discussion here is more cautious than elsewhere — one year on Compounds › Retatrutide TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Two things I would like separated before anyone answers on…	+92	97	3.6k	20h
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. A question about retatrutide discussion that I think…	+7	12	7.7k	2mo
Non-inferiority margins: how they are chosen and how they are abused — a second dataset Evidence › Trials randomised trial discontinuation & dropout intention to treat estimand Non-inferiority margins: how they are chosen and how they are abused — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Non-inferiority…	+32	37	574	5mo
Comparing my trajectory with the trial curves, carefully Outcomes › Progress reports DXA effect size long read data table Solved Posting this under the heading it deserves: Comparing my trajectory with the trial curves, carefully Everything below is what sits behind that. Maintenance rather than loss, which is the part of this that…	+86	92	54k	7mo